Characterization of the Evolution of the Pharmaceutical Regulatory Environment

References

1. 1.↵
   1. Hartmann M.,
   2. Hartmann-Vareilles F.

   Recent developments in European pharmaceutical law 2004: a legal point of view. Drug Information J. 2005, 39 (2),193–207.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Tancer R. S.,
   2. Mosseri-Marlio C.

   Evolution of pharmaceutical regulations and their consequences in the European Union and the United States. Thunderbird International Business 2002, 44 (2), 263–281.

   OpenUrl
3. 3.↵
   1. Li Bassi L.,
   2. Bertele V.,
   3. Garattini S.

   European regulatory policies on medicines and public health needs. Eur. J. Public Health 2003, 13 (3), 246–251.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Borchers A. T.,
   2. Hagie F.,
   3. Keen C. L.,
   4. Gershwin M. E.

   The history and contemporary challenges of the US Food and Drug Administration. Clinical Therapeutics 2007, 29 (1), 1–16.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   US Food and Drug Administration (FDA). Regulatory Information: Legislation. Department of Health and Human Services: Rockville, MD, 2007; http://www.fda.gov/RegulatoryInformation/Legislation/default.htm. Accessed October 30, 2011.
6. 6.↵
   US Supreme Court. United States v. Bacto-Unidisk, 394 U.S. 784, 1969; http://supreme.justia.com/cases/federal/us/394/784/case.html. Accessed October 30, 2011.
7. 7.↵
   US Congress. Food, Drug, and Cosmetic Act, SEC. 505. (21 USC §355) New Drugs. FDCA Amendment; Accessed 30 October 2011.
8. 8.↵
   United States Government Accountability Office. Improvement Needed in FDA's Post-market Decision-making and Oversight Process. Report to Congressional Requesters, Washington, DC, 2006.
9. 9.↵
   US FDA. FDA Strategic Action Plan: Charting Our Course for the Future; Department of Health and Human Services: Rockville, MD, 2007; http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/StrategicActionPlan/UCM061415.pdf. Accessed on October 30, 2011.
10. 10.↵
    1. Platt R.,
    2. Wilson M.,
    3. Chan K. A.,
    4. Benner J. S.,
    5. Marchibroda J.,
    6. McClellan M.

    The new Sentinel Network—improving the evidence of medical-product safety. N. Engl. J. Med. 2009, 361 (7), 645–647.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Psaty B. M.,
    2. Burke S. P.

    Protecting the health of the public—Institute of Medicine recommendations on drug safety. N. Engl. J. Med. 2006, 355 (17), 1753–1755.

    OpenUrlCrossRefPubMed
12. 12.↵
    Pharmaceutical Manufacturers of America. PhRMA Statement on Health Care Reform Coalition; Pharmaceutical Manufacturers of America: Washington, DC, 2009; http://www.phrma.org/media/releases/phrma-statement-healthcare-reform-coalition. Accessed October 30, 2011.
13. 13.↵
    Institute for Crises Management. News coverage of business crisis during 2008. Annual ICM Crisis Report, Louisville, Kentucky: 2009, 18 (1).
14. 14.↵
    1. Funning S.,
    2. Grahnen A.,
    3. Eriksson K.,
    4. Kettis-Linbald A.

    Quality assurance within the scope of good clinical practice (GCP)—What is the cost of GCP-related activities? A survey within the Swedish Association of the Pharmaceutical Industry (LIF)'s members. Quality Assurance J. 2009, 12 (1), 3–7.

    OpenUrl
15. 15.↵
    The European Medicines Agency (EMA). Road Map to 2010: Preparing the Ground for the Future; EMA: London, 2005. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000164.jsp&mid=WC0b01ac05800293fc. Accessed October 30, 2011.
16. 16.↵
    1. Bass S.,
    2. Klasmeier C.

    US Food and Drug Administration and European Medicines Agency Enter into New Good Clinical Practices Collaboration; Sidley Austin, LLP: New York, 2009.
17. 17.↵
    1. Sudhop T.,
    2. Brandt S.,
    3. Kiesinger-Allee K. G.,
    4. Keitel S.

    Pharmaceutical innovation: possibilities and limits of personalized medicine. Bundesgesundheitsbl–Gesundheitsforsch–Gesundheitsschutz 2008, 51, 675–688.

    OpenUrl
18. 18.↵
    1. Abraham J.,
    2. Lewis G.

    Harmonising and competing for medicines regulation: How healthy are the European Union's systems of drug approval? Social Science and Medicine 1999, 48 (11), 1655–1667.

    OpenUrl
19. 19.↵
    1. Epstein J.,
    2. Seitz R.,
    3. Dhingra N.,
    4. Ganz P. R.,
    5. Gharehbaghian A.,
    6. Spindel R.,
    7. Teo D.,
    8. Reddy R.

    Role of regulatory agencies. Biologicals. 2009, 37 (2), 94–102.

    OpenUrlPubMed
20. 20.↵
    1. Schwartzman D.

    Innovation in the Pharmaceutical Industry; Johns Hopkins University Press: Baltimore, MD, 1976.
21. 21.↵
    World Health Organization. 12th International Conference of Drug Regulatory Authorities Recommendations, 2006.
22. 22.↵
    1. Carney S.

    Interview: Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development. Drug Discov. Today 2005, 10 (21), 1411–1414.

    OpenUrlPubMed
23. 23.↵
    1. Woodcock J.

    The Role of Biotechnology and Bioinformatics in FDA's Critical Path Initiative. FDA: Rockville, MD, 2007; http://www.slidefinder.net/t/the_role_biotechnology_bioinformatics_fda/3066274. Accessed October 30, 2011.
24. 24.↵
    1. Woodcock J.,
    2. Woosley R.

    The FDA Critical Path Initiative and its influence on new drug development. Ann. Rev. Med. 2008, 59, 1–12.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    US FDA. Critical Path Opportunities Initiative; 2007; http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077248.htm. Accessed October 30, 2011.
26. 26.↵
    EMEA/SHMP Think-Tank Group. Final Report—Innovative Drug Development Approaches; Medicines Control Agency, 2007; http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004913.pdf. Accessed October 30, 2011.
27. 27.↵
    US FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products; 2004. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm. Accessed October 30, 2011.
28. 28.↵
    1. Merrill R. A.

    Modernizing the FDA: an incremental revolution. Health Affairs 1999, 18 (2), 96–111.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Worthen D. B.

    Pharmaceutical legislation: an historical perspective. International Journal of Pharmaceutical Compounding 2006, 10 (1), 20–28.

    OpenUrl
30. 30.↵
    1. Abraham J.,
    2. Davis C.

    Comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): implications for current regulatory thinking and policy. Social Science and Medicine 2005, 61 (5), 881–892.

    OpenUrl
31. 31.↵
    1. Shafiei N.,
    2. Ford J. L.,
    3. Morecroft C. W.,
    4. Lisboa P. J.,
    5. Taylor M. J.,
    6. Mouzughi Y.

    Transformation in the pharmaceutical industry—a systematic review of the literature. PDA J. Pharm. Sci. Technol. 2013; 67:105–122.

    OpenUrlAbstract/FREE Full Text